Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback